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Background: In 2005, the Democratic Republic of Congo (DRC) adopted artesunate and amodiaquine (ASAQ) as
first-line anti-malarial treatment. In order to compare the efficacy of the fixed-dose formulation ASAQ versus
artemether-lumefantrine (AL), a randomized, non-inferiority open-label trial was conducted in Katanga.
Methods: Children aged six and 59 months with uncomplicated Plasmodium falciparum malaria were enrolled and
randomly allocated into one of the two regimens. The risk of recurrent parasitaemia by day 42, both unadjusted
and adjusted by PCR genotyping to distinguish recrudescence from new infection, was analysed.
Results: Between April 2008 and March 2009, 301 children were included: 156 with ASAQ and 145 with AL. No
early treatment failures were reported. Among the 256 patients followed-up at day 42, 32 patients developed late
clinical or parasitological failure (9.9% (13/131) in the ASAQ group and 15.2% (19/125) in the AL group). After PCR
correction, cure rates were 98.3% (95%CI, 94.1-99.8) in the ASAQ group and 99.1% (95%CI, 94.9-99.9) in the AL group
(difference −0.7%, one sided 95% CI −3.1). Kaplan-Meier PCR-adjusted cure rates were similar. Both treatment
regimens were generally well tolerated.
Conclusion: Both ASAQ and AL are highly effective and currently adequate as the first-line treatment of
uncomplicated falciparum malaria in this area of Katanga, DRC. However, in a very large country, such as DRC, and
because of possible emergence of resistance from other endemic regions, surveillance of efficacy of artemisinin-
based combination treatments, including other evaluations of the resistance of ASAQ, need to be done in other
provinces.
Trial registration: The protocol was registered with the clinicaltrials.gov, open clinical trial registry under the
identifier number NCT01567423.
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Despite recent progress in access to effective preventive
and therapeutic measures to control malaria, it remains
one of the leading causes of morbidity and mortality
worldwide, and especially in Democratic Republic of
Congo (DRC) [1]. In this country, malaria cases was
reported to represent up to 68% of outpatient visits and
30% of hospital admissions and accounted for an esti-
mated 42% mortality in children under five, all over the
country [2]. Malaria is seasonal, with transmission peak-
ing during the rainy season from September to May and
Plasmodium falciparum accounts for nearly 95% of all
malaria cases in this region [3].
In 2005, following increased reports of sulphadoxine-
pyrimethamine (SP) resistance [4], the National Malaria
Control Programme the Ministry of Health of DRC
decided to replace SP by artesunate (AS) combined with
amodiaquine (AQ), as first-line treatment, following
WHO guidelines recommendation to use artemisinin-
based combination therapy (ACT) for uncomplicated
malaria [5]. The association was initially only available in
loose combination of ASAQ in blister pack.
Until 2007, the combination of artemether-lumefan-
trine (AL) was the only fixed-dose ACT registered to
international standards that was widely available in mal-
aria-endemic countries. A new fixed-dose combination
of artesunate and amodiaquine (ASAQ WinthropW),
developed by the Drugs for Neglected Diseases Initiative
(DNDi) in collaboration with Sanofi-Aventis, was pre-
qualified by the WHO in 2008.
Current international guidelines advocate that once a
new anti-malarial treatment is introduced in a country,
the efficacy of such novel regimens needs to be moni-
tored regularly in order to detect early signs of declining
efficacy, which can have implications for policy markers
[5]. The few studies conducted in eastern DRC showed
that the efficacy of ASAQ by day 28 varied between
84.9% and 93.3% in children less than 5 years old [4,6,7].
As DRC is a very large country of approximately
2,345,000 km2, repeated evaluations of the ACT efficacy
are needed in different regions.
Given that the transition in drug policy from a loose to
a fixed dose combination would be easier option for un-
complicated malaria treatment, it was decided to assess
the efficacy of the new fixed-dose combination of artesu-
nate and amodiaquine (ASAQ) in comparison with the
fixed-dose combination of artemeter and lumefantrine
(AL), in the province of Katanga, south-eastern DRC.
Methods
The aims of the study were to compare (i) treatment effi-
cacy of fixed-dose ASAQ and its alternative AL,
expressed as product limit estimates of failure from sur-
vival analysis and as simple proportions from perprotocol analysis, on day 42, and (ii) analysis of adjusted
and unadjusted results by genotyping.Study design and site
An open randomized study was conducted to test the
hypothesis that the risk of recurrent parasitaemia after
42 days is not inferior in the group receiving ASAQ regi-
men compared to the group receiving AL regimen. The
patients were recruited from the outpatient department
of the general reference hospital of Pweto, health district
of Pweto, province of Katanga, DRC, between April 2008
and March 2009 (Figure 1).
This protocol was registered with ClinicalTrials.gov,
under the idenfier number NCT01567423.Procedures
Children aged between six and 59 months and with a
body weight ≥ 5 kg were eligible for enrolment if they
had P. falciparum infections (density threshold at inclu-
sion between 2,000 and 200,000/μl), fever or history of
fever in the previous 24 hours, no signs of severe mal-
aria, no reported hypersensitivities of the studied drugs,
and no serious concomitant febrile illness [5].
The children included were randomized in one of the
two treatment arms, in a 1:1 ratio without stratification.
The randomization list was generated by a computer in
blocks of six. Treatment allocations were kept in sealed
and numbered opaque envelopes. Participants were en-
rolled in the same order in which they were diagnosed.
ASAQ (ASAQ WinthropW, Sanofi-Aventis) was admi-
nistered once daily for three days, as follows: one tablet
of artesunate 25 mg/amodiaquine 67.5 mg for children
between 5 to 8.9 kg, artesunate 50 mg/amodiaquine
135 mg for children between 9 to 17.9 kg. One tablet of
artemether 20 mg/lumefantrine 120 mg (CoartemW,
Novartis Pharma, Basel, Switzerland) was administered
twice daily for three days to children with a body weight
of 5 to 14.9 kg and two tablets were administered twice
daily for three days to children with a body weight of 15
to 24.9 kg. All doses were administered under direct ob-
servation for the three days. Full doses of drugs were re-
administered if a patient vomited within 30 min after re-
ceipt. Patients who vomited more than twice were
excluded from the study and were treated with oral quin-
ine 10 mg/kg/8 h for 7 days.
Signs of severe malaria or any other serious health con-
dition (e.g. severe malnutrition), intake of anti-malarial
treatment in the last seven days, and mixed malaria infec-
tion were also excluded from the study.
Clinical assessment (including measurement of axillary
temperature), tick and thin smears and haemoglobin
measurement were performed on days 2, 3, 7, 14, 21, 28,
35 and 42 or any day in between in the event of illness.
Figure 1 Map of Democratic Republic of Congo.
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Outcomes were classified according to 2009 WHO
guidelines as adequate clinical and parasitological re-
sponse (ACPR), early treatment failure (ETF), late clin-
ical failure (LCF), late parasitological failure (LPF) or
follow-up interrupted [8]. Follow-up interrupted
included treatment protocol violation, lost to follow-up,
use of other anti-malarials outside the study protocol or
withdrawal of consent prohibiting further follow-up.
Drug tolerability was also assessed clinically. An adverse
event was defined as any undesirable symptom in a pa-
tient during the study regardless of whether it was
related to the treatment.
PCR genotyping
In areas of intense transmission, where multiple genotype
infections are common [9], a second episode of malaria
or a recurrent parasitaemia during the drug-free follow-
up period may be due to the same infection or a different
infection (a recrudescence, thus a treatment failure, or a
new infection, respectively). To distinguish these two
events, polymorphic P. falciparum genes, such as the
merozoite surface protein 1 and 2 genes (msp1 and msp2)
and the glutamate-rich protein gene (glurp) weregenotyped by PCR, as previously described [10]. PCR
analyses, conducted at the Epicentre research base, Mbar-
ara, Uganda, were performed using paired samples from
all patients experiencing late clinical or parasitologic fail-
ure. Blood samples were collected on Whatman FTAW
Cards (GE Healthcare UK Limited, Buckinghamshire,
United Kingdom) on the day of enrollment and the day
treatment failure occurred. The genotypic profiles for
pre- and post-treatment parasites were compared;
patients in which pre- and post-treatment genotypes were
identical were considered as recrudescences and patients
in which pre- and post-treatment genotypes were differ-
ent were considered as new infections [11].
All ETFs were considered to be due to recrudescence.
Patients meeting the criteria for LCF or LPF in whom
genotyping was done; according to the results, patients
were classified as either (i) resolved by PCR and further
categorized as recrudescences or new infections or (ii)
unsuccessfully genotyped with the reason recorded
(missing sample, PCR not done or result inconclusive).
Ethics
This study underwent ethical review and was approved
by Ethical Committee of the School of Public Health,
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Médecins Sans Frontières and the Comité de Protection
des Personnes “Ile de France XI”, St Germain en Laye,
France. The study was authorized by the relevant health
authority. Written informed consent was obtained from
the parents or legal guardians of the enrolled children.Table 1 Baseline characteristics of trial participants, by
treatment group
ASAQ AL
Patients included 156 145 -
Age (months) 27.6 (6–59; 14.3) 27.4 (6–59; 15.0)
Sex (female) 83 (53.3%) 69 (47.6%)
Weight (kg) 10.3 (5.1-17.0; 2.7) 10.2 (5.3-16.0; 2.6)
Axillary temperature (°C) 37.6 (34–40.5; 1.3) 37.6 (35.2-40.0; 1.1)
Patients with fever
(T°≥ 37.5°C)
79 (50.6%) 71 (48.9%)
Haemoglobinaemia (g/dL) 9.0 (4.0-13.3; 1.9) 9.0 (5.3-15.5; 2.1)
Anaemia 5-< 8 g/dl 50 (32.0%) 51 (35.2%)
8-11 g/dl 83 (53.2%) 65 (44.8%)
> 11 g/dl 23 (14.8%) 29 (20.0%) -
Geometric mean parasite
density (/μL) (IQR)
17111 (34674) 14886 (53420)
Proportion≥ 100,000 para/μL 13 (8.3%) 11 (7.5%)
Patients with gametocytes 9 (5.8%) 7 (4.8%)
Data are number (%) or mean (range; SD), unless otherwise indicated.Statistical analyses
Based on previous data for AL efficacy [12-14], efficacy
rate, defined as the PCR-adjusted parasitological cure
rate at day 42, was estimated of 95% for both treatments.
With a 7% non-inferiority margin, a power of 80%, and a
test significant level (one side) of 5%, the sample size
required to conclude to non inferiority was 150 per treat-
ment group, taking into account an increase of 20% for
loss to follow-up or premature withdrawals [nQuery Ad-
visor v6].
The primary outcome was the PCR-adjusted parasito-
logical cure rate up to day 42 of the follow-up period.
Two analytical approaches were used to assess efficacy
data. First, a per protocol (PP) analysis was performed
including only the patients who were followed through-
out the protocol, defined follow-up period and in whom
a clear treatment outcome can be determined. The risk
of failure for each treatment group was calculated as the
proportion of patients classified as failure (the numer-
ator) divided by the number of patients in the evaluable
population (the denominator). In the second approach,
survival analysis was performed and patients with incom-
plete follow-up who did not reach the primary outcome
interest were included in the analysis as non-failures, but
censored on the last day of follow-up. The risk of failure
was calculated using the Kaplan-Meier product limit for-
mula with data censored for patients who were not clas-
sified as failures and with interrupted follow-up. Patients
wrongly included, who did not meet study inclusion cri-
teria, were excluded from both analyses.
In the PP analysis (adjusting by genotyping), the evalu-
able population included only patients classified as
ACPR, ETF or LCF/LPF due to recrudescence. In the
survival analysis, the evaluable population for adjusted
and unadjusted calculations included all patients enrolled
in the study, with the exception that LCF/LPF outcomes
with unsuccessful genotyping outcomes were excluded
from the adjusted calculations. For the unadjusted calcu-
lations, patients with follow-up interrupted and non-
falciparum new infections were censored on the last day
of observation. For the adjusted calculations, censored
patients also included those with new P. falciparum
infections.
Other variables were compared using the chi2 test or
Fisher’s exact test for variables and Student’s test for
continuous variables.Data were double entered and validated using Epidata
version 3.1 (Odense, Danemark). All analyses were per-
formed with Stata, version 10 (Stats-Corp, College Sta-
tion, Texas). A p-value< 0.05 was considered statistically
significant.
Results
Between April 2008 and March 2009, a total of 1,993
patients were screened, 301 children aged between six
and 59 months were enrolled in the two treatment arms,
156 with ASAQ and 145 with AL. The mean age of
patients at baseline was 27.5 months (range 6–
59 months) and 152 (50.5%) were females. There were
no differences between treatment arms at study inclu-
sion, for all variables studied, including demographic,
clinical and laboratory characteristics, confirming ad-
equate randomization (Table 1).
The clinical trial profile is presented in Figure 2.
Thirty-one (10.3%) were lost during follow-up (26 before
day 28, five on or after day 28); and 14 (4.6%) were with-
drawn (all before day 14). The reasons for withdrawal
were co-infection with P. falciparum and Plasmodium
malariae at study inclusion (8/14), taking another anti-
malarial drug (1/14), severe anaemia (1/14) and other
violation protocol (4/14). All these 14 patients were
excluded from the analyses.
Adequate clinical and parasitological response and
treatment cure rates
Among the 256 patients still followed-up at day 42, ad-
equate clinical and parasitological response was observed
in patients: 90.1% (118/131) in the ASAQ group and
68 excluded
- infection due to non-falciparum species (8)
- parasite density < 2 000 ou > 200 000 (54) 
- severe anemia (1), severe malaria (2) 
- severe malnutrition (1) 
- distance > 2h from hospital (2) 
Refusal of parents (6) 
Lost to follow-up (n=15) Lost to follow-up (n=11) 
Protocol deviations (n=7) Protocol deviations (n=7) 
Lost to follow-up (n=3) Lost to follow-up (n=2) 
156 children in the ASAQ group 145 children in the AL group
134 children in D28 analysis 127 children in D28 analysis
131 children in D42 analysis 125 children in D42 analysis 
301 children randomly allocated 
307 children eligibles 
368 children with a body weight 
> 5kg, fever or history of fever 
and confirmed malaria 
1 993 children between 6 and 59 months 
screened
Figure 2 Trial profile. ASAQ, artesunate-amodiaquine; AL, artemeter-lumefantrine.
Espié et al. Malaria Journal 2012, 11:174 Page 5 of 9
http://www.malariajournal.com/content/11/1/17484.8% (106/125) in the AL group. Overall, no patient
experienced early treatment failure, and 32 patients
developed late clinical or parasitological failure (9.9%
(13/131) in the ASAQ group and 15.2% (19/125) in the
AL group) (Table 2).
Among the 32 children with recurrent parasitaemia
after day 7, PCR genotyping was successfully performed
on 31 (96.8%) of 32 blood samples (Table 2). PCR-Table 2 Treatment outcomes after 42 days for episodes of
uncomplicated Plasmodium falciparum malaria
Treatment outcome Treatment group, No. (%)
ASAQ (n =156) AL (n = 145)
No treatment outcome 25 (16.0) 20 (13.8)
Lost to follow-up 18 13
Other protocol deviations 7 7
Adequate clinical and
parasitological response
118 (75.6) 106 (73.1)
Recurrent parasitaemia
(including LCF and LPF)
13 (7.4) 19 (13.1)
Recrudescence 2 1




Genotyping not performed 1 0corrected cure rates by day 42 were 98.3% (95%CI, 94.1-
99.8) following completion of the ASAQ regimen and
99.1% (95%CI, 94.9-99.9) following completion of the AL
regimen (difference −0.7%, one sided 95% CI −3.1).
Table 3 and Figure 3 gives the results of unadjusted
and PCR-adjusted Kaplan Meier cure rate analysis at day
42.
Parasite and fever clearance, and gametocyte carriage
Clearance of fever (defined as a temperature <37.5°C)
was more rapid in patients given ASAQ than in patients
given AL, one day after treatment initiation. Among pa-
tient who had fever at inclusion, one (1.3%) of 79 ASAQ
recipients and eight (11.3%) of 71 AL recipients
remained febrile (p-value = 0.002). By day 2, nearly all
fevers had resolved and the two regimens did not differ
(p-value = 0.38). Rapid clinical improvement was
recorded within the two treatment groups.
By day 2, parasite clearance did not differ between the
two regimens, with positive slide results observed for
nine (6.0%) of 150 ASAQ-treated patients and for seven
(4.9%) or the 143 AL-treated patients (p-value = 0.68). By
day 3 and day 7, only one patient (respectively in the AL
group and in the ASAQ group) had not yet cleared all
parasites.
At baseline, gametocyte carriage rates were low in both
regimen groups (Table 1). Gametocytes were detected
Table 3 Efficacy outcome for ASAQ and AL on day 42, calculated by PP analysis and Kaplan-Meier analysis
PP cure rate analysis Kaplan Meier cure rate analysis
ASAQ AL ASAQ AL
PCR unadjusted
n/N 13/131 19/125 12/156 18/145
% efficacy [CI95%] 90.1 [83.6-94.6] 84.8 [77.3-90.6] 90.9 [84.6-94.8] 85.8 [78.4-90.8]
% difference (LLCI*) −5.2 (−0.02)
PCR adjusted
n/N 2/120 1/107 2/146 1/137
% efficacy [CI95%] 98.3 [94.1-99.8] 99.1 [94.9-99.9] 98.4 [93.8-99.6] 99.2 [94.3-99.9]
% difference (LLCI*) −0.7 (−3.1)
*LLCI : lower limit of the one-sided 90%CI.
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day 2, 11.9% and 4.8%, by day 3, 10.6% and 4.2%, and by
day 7, 6.3% and 1.5% (p-value< 0.05).Adverse events
Both treatment regimens were generally well tolerated.
Twelve patients (ten (6.4%) in the ASAQ group and two
(1.4%) in the AL group) vomited within 30 min after the
administration of the dose; nine of them (all in the
ASAQ group) had received a second dose and none was
excluded from the study.
No deaths occurred during the follow-up period, but
six patients (one in the ASAQ group and five in the AL
group) developed moderate or severe adverse events
associated with clinically suspected severe malaria (an-
aemia, lethargy, convulsions). All patients were trans-
fused and one received the rescue treatment consisting
on intravenous quinine (loading dose 20 mg/kg given
over 4 hours, then 10 mg/kg given 8 hours after the
loading dose was started, followed by 10 mg/kg every 8
hours for 7 days). Four of these six patients (all in the
AL group) were hospitalized for two to six days. Thus,
these events could not be attributed to the intervention
drugs.
Other mild side-effects were less common and were
not related to a specific treatment: lower acute respira-
tory infections (54.6% in the ASAQ group and 51.3% in
the AL group), conjunctivitis (16% in the ASAQ group
and 10.8% in the AL group), abdominal pains and diar-
rhoea (8% in the ASAQ group and 14.9% in the AL
group).Figure 3 Kaplan Meier curves, a) PCR-unadjusted b) PCR-adjusted.
ASAQ, artesunate-amodiaquine; AL, artemeter-lumefantrine.Discussion
The results of this randomized trial of Congolese chil-
dren in Katanga province with uncomplicated falciparum
malaria and follow-up patients for 42 days show that the
efficacy of fixed-dose combination of ASAQ is non-infer-
ior to fixed-dose combination of AL, with regard to the
margin prespecified at 7%.High PCR adjusted cure rates of 98.3% to 98.4% (de-
pending on the analysis population) were seen in patients
assigned to ASAQ, compared with rates of 99.1% to
99.2% in patients assigned to AL. These results are com-
parable to those from previous studies where AS+AQ
were routinely used as multiple tablets (loose combin-
ation) in other sub-Saharan countries [12-14], but higher
than those reported by Bonnet et al. in Equatorial
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from recent studies which studied efficacy of fixed-dose
combination of ASAQ after 28 days of follow-up [15,16].
As with other malaria efficacy studies conducted in
areas of high transmission [13], the unadjusted efficacy
rates, which were significantly different between the two
treatment arms, largely reflect a difference in rates of
new infection than in rates of recrudescence. Thus, in
this study, a significant proportion of new infections was
reported, most prominently in the AL group, which re-
flect partially the prophylactic effect of the drugs.
In this study, the adjusted estimates of treatment effi-
cacy derived from the two statistical approaches were
not significantly different. New infection with P. falcip-
arum usually constitutes an additional confounding fac-
tor for the adjusted analysis. Whereas patients with such
infections are removed from the PP analyses, they are
censored in the survival analysis after contributing a
period of observation to the cumulative risk during
which treatment failure was not observed [17]. This dis-
crepancy was particularly apparent in the high transmis-
sion sites in Africa where new infections were highest,
but it was not observed in this study.
Survival analysis allows for more available data to con-
tribute to the analysis, thus increasing the precision of
the derived estimates. It avoids systematic biases intro-
duced by dropping from the analysis patients who do
not complete follow-up [8,18,19], even if in this study,
the proportion of these patients was 10.3%, which could
be considered as acceptable.
During the first days of treatment, a rapid decrease of
fever, parasitaemia and gametocyte carriage was observed
in the two regimen groups. These findings confirmed the
results of efficacy studies on artemisinin-containing com-
bination which led to lower gametocyte carriage, improv-
ing the cure rates, decreasing the transmission of
falciparum malaria and reducing the spread of resistance
to non-artemisinin drugs [20,21]. Parasite clearance has
became an important indicator in the evaluation of ACT,
especially following the emergence of artemisinin resist-
ance in Cambodia and the Thai-Burmese border [22-24].
Here the proportion of patients with low parasitaemia at
day 2 and 3 is giving new important indication of the
parasite early response following ACT [25].
This study showed that both combinations were well
tolerated, with only 6% of children with drug-induced
vomiting. Nevertheless, differents between treatment
arms were observed in the first few days following treat-
ment; vomiting was higher in the ASAQ group com-
pared to AL. Only four patients developed severe
malaria, and no deaths occurred during the course of the
study. It is worth mentioning that the study was not
designed nor power to compare tolerabilty between the
two combinations. The ASAQ FDC presents theadvantage of requiring one intake per day while AL is
twice per day [26]. However, the tolerability, in particu-
lar vomiting may impact the effectiveness of the treat-
ment and should be assessed, particularly while used in
home management of malaria [27] or as intermittent
preventive therapy in children [28].
A limitation of this study was that pharmacology mea-
sures were not performed. It would improve the differen-
tiation between true recrudescence to a problem of
absorption [29]. The limited reliability of the electric
supply and the absence at that time of standardized PK
measure on filter paper were among the reasons why
these measures were not implemented.
According to WHO guidelines, which recommend a
change in anti-malarial treatment policy when the cure
rate for the current recommended therapy falls below
90% [5], this study showed that both ASAQ and AL are
currently adequate as the first-line treatment of uncom-
plicated falciparum malaria in this area of the Katanga
province. Surveillance of ACT efficacy in a very large
country such as DRC remains a technical, financial and
logistic challenge, illustrated by the limited number of
published and unpublished efficacy studies in the past
decade [4,6,7,30].
While emergence of artemisinin resistance in South
East Asia is of serious concern [22,23], possible emer-
gence of resistance from other endemic regions is trig-
gering renewed attention in monitoring anti-malarial
efficacy. More financial resources are now available in
particular from Global Funds, World Bank or PMI to
support this surveillance. However, the current recom-
mended protocol for monitoring anti-malarial efficacy
can be very challenging to implement, in particular, in
remote study sites. In this particular study, the difficul-
ties to supply equipment, drugs, consumables, establish-
ing external quality assurance processes and accessing
the site were among daily challenges. The follow-up of
patients in particular in a border area was also a major
issue for the study team. Research is needed to develop
simpler methods to monitor efficacy, e.g., shorter follow-
up of patients, and validate molecular marker of artemi-
sinin resistance.
Initiatives, including development of paediatric formu-
lations, home-based management of malaria and improv-
ing public sector procurement and supply chains should
make ACT more accessible for sub-Saharan African chil-
dren [31,32].
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